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Burkholderia cepacia complex (Bcc) isolates from 39 CF patients and 25 non-CF patients in New Zealand were speciated and characterised
using the multilocus sequence typing (MLST) scheme for Bcc. B. multivorans predominated in CF patients (31/39, 79.5%) and in non-CF patients
(7/25, 28%). Sequence types (ST) with an international distribution were identified (27/64, 42.2%) among the New Zealand Bcc isolates. MLST
revealed a high level of diversity among Bcc isolates in CF patients indicating a lack of person-to-person transmission. Non-CF patients showed
less diversity in MLST types, however, individuals with shared STs were geographically and chronologically separated. The use of MLST
analysis allows continued surveillance of isolates with the potential to identify outbreaks. The identification of internationally distributed strains
may provide an indicator of the relative transmissibility and infectivity of these strains and warrants further investigation.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Burkholderia cepacia complex; Cystic fibrosis; MLST; International; New Zealand; Epidemiology; Genotype1. Introduction
The Burkholderia cepacia complex (Bcc) has emerged as an
important opportunistic pathogen in the respiratory tract of
cystic fibrosis (CF) patients and also causes serious infections in
non-CF patients [1]. The complex is made up of 17 genetically
distinct species [2] all of which are capable of causing lung
infection in CF patients [3] and serious morbidity and mortality
[4]. Bcc infection in non-CF patients is most often associated
with an underlying medical condition and can cause serious
conditions such as septicaemia [5] and bronchiectasis [6].
Large outbreaks of Bcc can occur in CF patients and result
from exposure to a contamination source or patient-to-patient
spread. In the non-CF patient infection is usually due to
environmental exposure rather than person-to-person spread.
There are approximately 400 people in New Zealand with
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doi:10.1016/j.jcf.2010.08.011CF patients range from 2.5 to 22% [7–9]. Little is known about
the distribution and predominance of Bcc species causing
infection among CF and non-CF patients within New Zealand.
We identified 64 patients who had submitted Bcc positive
clinical samples between 2002 and 2007: 39 Bcc non-duplicate
isolates from the lungs of CF patients and 25 Bcc non-duplicate
isolates from various sites in non-CF patients.
The aim of this study was to characterise the species
distribution of B. cepacia complex in CF and non-CF patients in
New Zealand using molecular techniques, to identify and
compare the most common species in CF and non-CF patients
and to look for evidence of an endemic infection amongst CF
patients.2. Material and methods
2.1. Bacterial isolates
Samples identified as belonging to the Bcc were collected
between 2002 and 2007. In total 64 clinical isolates were
collected, each from a single patient. Laboratory identificationd by Elsevier B.V. All rights reserved.
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(BCSA) and standard biochemical testing [10]. The 39 isolates
from CF patients were cultured from sputum samples except for
one isolated by cough plate culture. The 25 isolates from non-
CF patients were cultured from a number of sites, including
blood (n=13), lung aspirate (n=2), catheter (n=2), ear (n=2),
leg ulcer (n=1), wound (n=1), urine (n=2) and placenta (n=1).
No source information was available for one non-CF isolate.
2.2. DNA extraction
DNA used for recA PCR and multilocus sequence typing
(MLST) analysis was prepared by resuspending several colonies
from a 24 hour plate culture in lysis buffer (0.25% (V/V) sodium
dodecyl sulphate, 0.05 M NaOH) and heating the suspension
at 95 °C for 15 min, then adding 180 μl of molecular grade water.
The neat supernatant was used as a source of DNA template for
PCR assays.
2.3. recA and MLST PCR and sequence analysis
PCR and sequence analysis of the recA gene was performed
using Bcc specific primers BCR1 and BCR2 as previously
described and sequenced using the MLST recA sequencing
primers recA-F and recA-R [11,12]. MLST was performed as
described by Baldwin et al. [12]. The extended MLST protocol
for Burkholderia species [13] was used where a low quality
amplicon was produced using the original primer set. Sequencing
reactions were run on an Applied Biosystems 3130xl Genetic
Analyzer. Sequences were aligned using the Bionumerics
software (Applied Maths), and allele and sequence types (STs)
were identified. Novel alleles and STs were submitted to the
B. cepacia MLST database for assignation.
3. Results
3.1. recA PCR and sequencing
All 64 isolates were speciated using the recA sequence. The
most common Bcc species identified among the 39 New
Zealand CF patients was B.multivorans (31/39, 79.5%), followed
by B. cenocepacia (5/39, 12.8%), B. stabilis (2/39, 5.1%) and
B. vietnamiensis (1/39, 2.6%). Among the 25 non-CF isolates
recA analysis identified six species, B multivorans (7/25, 28%),
B. stabilis (6/25, 24%), B. lata (5/25, 20%), B. cenocepacia (5/25,
20%), B. cepacia (1/25, 4%), and B. seminalis (1/25, 4%).
3.2. MLST PCR and sequencing
Bcc speciation by MLST analysis was in agreement with
recA speciation for 63 of the 64 isolates. A single non-CF
isolate, ESR622 (Table 1), was initially speciated as B. cepacia
by recA sequence analysis, however, characterisation by MLST
showed this isolate was B. contaminans.
The MLST scheme revealed a high degree of diversity in
both CF and non-CF populations. Among the 64 Bcc isolates 45
STs were identified (Table 1). A total of 30 novel STs, firstdescribed in this study, were identified. Of these 19 were from
CF isolates and 11 were from non-CF isolates. Of the 64
isolates, 27 (42.2%) had STs with an international distribution.
Eight STs were found in two or more CF isolates: ST-408,
ST-412, ST-417 and ST-274 were from sibling pairings,
whereas ST-16, ST-52, ST-181 and ST-439 were from cases
with no sibling relationship. The most common ST among CF
patients was ST-274 (n=3), of which two were from siblings
and the third was from an individual from the same geographical
region and city.
Among non-CF isolates three STs were associated with two
or more isolates. These were identified in B. lata (ST-103, n=5)
and B. stabilis (ST-51, n=3; ST-52, n=2).
It is unlikely that person-to-person spread was involved in
the non-CF population as the patients were separated temporally
and geographically.
Three STs, ST-52, ST-190 and ST-374 were common to both
CF and non-CF patients (Table 1). The two ST-190 isolates
were obtained 2 years apart and from different locations,
making a common link unlikely. In contrast, ST-52 was
identified in two CF and two non-CF patients and three of these
patients were from Auckland. ST-374 was isolated from one CF
and one non-CF patient in Waikato. For both these STs each
isolate was obtained at different times making it less likely that
person-to-person spread was responsible, although the possi-
bility of a common source of infection cannot be excluded.
4. Discussion
The distribution of Bcc species between CF and non-CF
isolates differed by composition and the proportion of species in
both groups. B. multivorans, for example, was responsible for
79.5% of the infections in patients from the CF group, but only
28% in the non-CF group. B. lata, a major component of non-
CF isolates was not identified in the CF group. Differences in
species proportions and distribution between the groups
could be due to niche adaptations where CF isolates especially
B. multivorans, are better adapted to infection of the CF lung
and non-CF isolates to other sites [6]. Investigating these dif-
ferences may be useful in determining virulence mechanisms
required for infection of the CF lung and of other sites, such as
the blood in non-CF infections.
The prevalence of B. multivorans in the CF group was
proportionally higher than observed in the United States [14],
Canada [4] and Australia [15], where B. cenocepacia is the
predominant Bcc species in CF patients. It has been reported
that B. multivorans is now the predominant Bcc species in
Belgium [16], France [17], the United Kingdom, and, as
this study showed, in New Zealand. In the United States,
B. multivorans has become the most commonly isolated Bcc
species from new CF patients [18]. Increased infection control
measures are most likely the reason for the relative decline in
B. cenocepacia infections [19] making environmental acquisi-
tion of B. multivorans more likely.
The diversity of the MLST types observed suggests patients
in New Zealand are most likely to acquire Bcc infection from
environmental sources as there is little evidence of person-to-
Table 1
Sequence types and Burkholderia cepacia complex characteristics in New Zealand CF and non-CF patients.
Species ID ST Date of sampling
month/year
Geographical region Source Sample type International
distribution
B. cenocepacia IIIA ESR587 28 09/2005 Auckland CF Sputum INT
B. cenocepacia IIIB ESR506 39 07/2004 Canterbury CF Sputum INT
ESR474 410 07/2003 Auckland CF Sputum NZ
ESR524 413 08/2003* Bay of Plenty CF Sputum NZ
ESR528 414 08/2004 Taranaki CF Sputum NZ
B. multivorans ESR088 16 01/2003 Auckland CF Sputum INT
ESR581 16 08/2004 Auckland CF Sputum INT
ESR316 17 03/2003 Auckland CF Sputum INT
ESR199 181 03/2003 Auckland CF Sputum INT
ESR104 181 02/2007 Waikato CF Sputum INT
ESR323 190 03/2005 Waikato CF Sputum INT
ESR253 195 03/2006 Waikato CF Sputum INT
ESR454S 274 07/2003 Otago CF Sputum INT
ESR409S 274 06/2004 Otago CF Sputum INT
ESR121 274 02/2006 Otago CF Sputum INT
ESR562 374 11/2002 Waikato CF Sputum INT
ESR771 406 11/2004 Waikato CF Sputum NZ
ESR779 407 12/2003* Hawke's Bay CF Sputum NZ
ESR283S 408 04/2004 Waikato CF Sputum NZ
ESR600S 408 09/2004 Waikato CF Sputum NZ
ESR375 411 05/2006 Canterbury CF Sputum NZ
ESR668S 412 10/2004 Canterbury CF Sputum NZ
ESR722S 412 10/2004 Canterbury CF Sputum NZ
ESR031 415 01/2003 Canterbury CF Sputum NZ
ESR083S 417 02/2003 Auckland CF Sputum NZ
ESR422S 417 06/2004 Hawke's Bay CF Sputum NZ
ESR481 418 07/2004 Auckland CF Sputum NZ
ESR285 439 04/2004 Auckland CF Sputum INT
ESR124 439 01/2006 Auckland CF Sputum INT
ESR408 440 06/2005 Taranaki CF Sputum NZ
ESR395 441 05/2006 Canterbury CF Cough plate NZ
ESR487 442 06/2006 Wellington CF Sputum NZ
ESR303 443 04/2007 Auckland CF Sputum NZ
ESR107 449 02/2002 Otago CF Sputum NZ
ESR297 450 05/2005 Taranaki CF Sputum NZ
ESR322 606 05/2007 Nelson CF Sputum NZ
B. stabilis ESR285 52 05/2002 Auckland CF Sputum NZ
ESR011 52 12/2003 Auckland CF Sputum NZ
B. vietnamiensis ESR629 405 09/2004 Waikato CF Sputum NZ
B. cenocepacia IIIA ESR511 602 08/2005 Auckland Non-CF Urine NZ
ESR183 608 01/2006 Bay of Plenty Non-CF Urine NZ
ESR170 609 03/2007 Auckland Non-CF Blood NZ
ESR460 610 06/2007 Auckland Non-CF n/a NZ
B. cenocepacia IIIB ESR305 338 05/2006* Auckland Non-CF Blood INT
B. contaminans ESR622 604 09/2006 Auckland Non-CF Aspirate NZ
B. lata ESR106 103 02/2003 Auckland Non-CF Blood INT
ESR254 103 04/2004 Auckland Non-CF Blood INT
ESR531 103 08/2004 Bay of Plenty Non-CF Blood INT
ESR072 103 02/2005* Bay of Plenty Non-CF Blood INT
ESR045 103 01/2007 Bay of Plenty Non-CF Blood INT
B. multivorans ESR385 190 05/2007 Auckland Non-CF Ear INT
ESR641 374 09/2003 Waikato Non-CF Blood INT
ESR152 601 03/2005 Waikato Non-CF Blood NZ
ESR584 603 09/2006 Bay of Plenty Non-CF Blood NZ
ESR768 605 11/2006 Auckland Non-CF Ear NZ
ESR478 607 07/2007 Auckland Non-CF Wound NZ
ESR535 613 08/2006 Otago Non-CF Placenta NZ
B. seminalis
B. stabilis
ESR037 589 01/2005 Auckland Non-CF Aspirate NZ
ESR385 51 05/2004 Auckland Non-CF Leg ulcer INT
ESR409 51 06/2005 Auckland Non-CF Catheter INT
ESR321 51 06/2006 Auckland Non-CF Catheter INT
ESR520 52 07/2004 Southland Non-CF Blood NZ
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Table 1 (continued)
Species ID ST Date of sampling
month/year
Geographical region Source Sample type International
distribution
B. stabilis ESR637 52 10/2005 Auckland Non-CF Blood NZ
ESR320 480 05/2004 Auckland Non-CF Blood INT
S = sibling relationship, n/a = information not available.
NZ = New Zealand only.
INT = international distribution, MLST profiles also identified overseas.
* = date received in lab, no isolation data available.
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same sequence type in CF-siblings shows person-to-person
spread of B. multivorans is possible or may show siblings can
acquire the same strain from the shared environment.
In the non-CF group B. stabilis and B. lata were responsible
for 44% of Bcc infections. MLST analysis showed a low level
of diversity among these isolates. The five B. lata isolates were
represented by a single type, ST-103, and the six B. stabilis
isolates were represented by three types, with ST-51 being the
most common (n=3) (Table 1). It is unlikely these common
strains are the result of person-to-person spread, due to
separation by geographical region and time. The ST-103 and
ST-51 strains may therefore represent acquisition from a
common source, or that these strains are more adapted to
infecting sites other than the lung. B. lata was only isolated
from the blood of non-CF patients. It should be noted that
B. lata ST-103 has been isolated in New Zealand (BCC-1406)
as an industrial process contaminant. The true source of this
isolate is unknown; however, if the source were associated with
the manufacture of medical equipment or disinfectants this may
provide a common infection source of the five patients for this
rarely isolated species.
This is the first time the species B. contaminans, B. lata, and
B. seminalis have been identified in New Zealand and have
only recently been described in the literature [3].
The sequence types identified in New Zealand included
strains with an international distribution (27/64, 42.2%). ST-16
(Table 1), for example, caused an outbreak in France [20] and
has also been isolated in five other countries (France, Belgium,
Canada, US, Australia) [19]. Epidemiology is important
for the identification of bacterial species with enhanced pathogenic
potential. Epidemic strains of B. cenocepacia (ST-28 and ST-39)
were identified in CF patients in New Zealand. Epidemic strains
have caused a number of outbreaks worldwide and ST-28 is
associated with the highly transmissible E12 lineage. The presence
of these types in New Zealand CF patients highlights the need
for continued infection control vigilance by the CF community
and health professionals.
The diversity of isolates identified and the lack of person-to-
person spread between non-siblings suggest infection control
measures inNewZealand hospitals treatingCF patients have been
successful. Alternatively, the low number of CF patients in New
Zealand (n=400) may be protective against person-to-person
spread in the clinical setting. All CF patients are screened for
Bcc infection; if present the individual is discouraged from
attending events where CF patients are likely to gather. Infectioncontrol of non-CF patients who harbour Bcc should include
isolation from immuno-compromised and CF patients.
The use of recA sequence analysis and MLST allows
continued surveillance of isolates from CF patients and the
identification of outbreaks. The identification of strains with an
international distribution may also provide an indicator of their
relative transmissibility and warrants further investigation.Acknowledgments
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